Skip to main
INCY

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 30%
Buy 15%
Hold 55%
Sell 0%
Strong Sell 0%

Bulls say

Incyte is currently undervalued with its diverse drug portfolio to drive long-term growth, an expected $2-3 billion in peak annual sales from multiple asset indications, stabilized or low costs due to resolution of CMS Medicaid dispute, the potential for increasing profitability through low priced topical ruxolitinib reducing net revenue pressure, and the recent acquisition of Star Therapeutics expanding the pipeline with high potential assets.

Bears say

Incyte is making strategic acquisitions to expand its hematology franchise and offset the expected impact of the LOE of its leading drug Jakafi. While the acquired drug VGA039 has promising attributes, such as a manageable regulatory path and potential for significant market expansion, there are also conservative elements in the company's guidance. Analysts believe that Incyte's potential peak sales for VGA039 may be underestimated, and a successful launch could lead to upside in stock performance.

Incyte (INCY) has been analyzed by 20 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 15% recommend Buy, 55% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 20 analysts, Incyte (INCY) has a Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $109.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $109.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.